Cargando…

A45 INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR IS ASSOCIATED WITH AN ATTENUATED ANTIBODY RESPONSE TO BNT162B2 SARS-COV-2 VACCINE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS

BACKGROUND: Adult data have shown that Infliximab (IFX) impairs the antibody response to a single dose of the mRNA-BNT162b2 SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD). The true impact of IFX on SARS-CoV-2 vaccine efficacy in pediatric IBD (PIBD) patients is unknown. AIMS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawrence, S, Shire, Z, Reicherz, F, Lavoie, P, Jacobson, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859343/ http://dx.doi.org/10.1093/jcag/gwab049.044

Ejemplares similares

A37 FECAL CALPROTECTIN IN A PEDIATRIC, POPULATION-BASED STUDY: UTILITY IN DIAGNOSIS AND INFLAMMATORY BOWEL DISEASE MONITORING
por: Smyth, M, et al.
Publicado: (2023)

A23 ESTIMATING INDIRECT AND OUT-OF-POCKET COSTS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE: A NATION-WIDE CROSS-SECTIONAL ANALYSIS
por: El-Matary, W, et al.
Publicado: (2022)

A233 CHARACTERIZATION OF THE DUODENAL MICROBIOME IN PEDIATRIC CELIAC AND INFLAMMATORY BOWEL DISEASE PATIENTS
por: Manoogian, J, et al.
Publicado: (2022)

A189 INFLAMMATORY BOWEL DISEASE IN PEDIATRIC PATIENTS POST RENAL TRANSPLANT:A CASE SERIES
por: Sethuraman, A, et al.
Publicado: (2022)

A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION
por: Crowley, E, et al.
Publicado: (2022)

A28 RESPONSE RATE OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PATIENTS TO ANTI-TNF TREATMENT IS HIGHER THAN PREVIOUSLY REPORTED, BUT HIGHER DOSING IS REQUIRED-A LARGE TERTIARY SINGLE CENTER EXPERIENCE
por: Eindor, A, et al.
Publicado: (2022)

A162 CHRONIC OPIOID THERAPY IS ASSOCIATED WITH INCREASED HEALTH SERVICES UTILIZATION AND DIRECT HEALTHCARE COSTS: A POPULATION-BASED STUDY
por: Kuenzig, E, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2021)

A152 NATURAL HISTORY OF SMALL BOWEL STRICTURES IN CROHN’S DISEASE
por: Vu, D C, et al.
Publicado: (2022)

A109 PATIENTS’ DESCRIPTIONS OF THEIR LAST BOWEL MOVEMENT BEFORE COLONOSCOPY CORRELATES STRONGLY WITH THEIR BOSTON BOWEL PREPARATION SCALE (BBPS) SCORE WHEN ASSESSED USING A STANDARDIZED METHOD
por: Akman, O, et al.
Publicado: (2022)

A183 TELEHEALTH USE IN RURAL SASKATCHEWAN AND INFLAMMATORY BOWEL DISEASE OUTCOMES
por: Patterson, M, et al.
Publicado: (2021)

A120 AUTOMATED BOWEL PREPARATION DETECTION WITH DEEP. CONVOLUTIONAL NEURAL NETWORKS
por: Low, D J, et al.
Publicado: (2022)

A45 FIBER-FREE DIET REDUCES BACTEROIDES ABUNDANCE AND PREVENTS MUCUS DEGRADATION IN MICE COLONIZED WITH MICROBIOTA FROM PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Rabbia, V, et al.
Publicado: (2023)

A73 CANADIAN INFLAMMATORY BOWEL DISEASE MOBILE APPS: CURRENT LANDSCAPE AND NEEDS
por: Chiew, B A, et al.
Publicado: (2022)

A164 RISKS OF SKIN CANCERS PRE- AND POST-INFLAMMATORY BOWEL DISEASE DIAGNOSIS
por: Narous, M, et al.
Publicado: (2022)

A155 ASEPTIC ABSCESS SYNDROME IN INFLAMMATORY BOWEL DISEASE: A CASE REPORT
por: Tam, L, et al.
Publicado: (2022)

A51 ROLE OF GUT MICROBIOTA IN THE EPISODIC NATURE OF SYMPTOMS IN IRRITABLE BOWEL SYNDROME
por: Mohan, V, et al.
Publicado: (2022)

A53 FECAL BIOACTIVE PHOSPHOLIPIDS AS TRIGGERS OF INTESTINAL HYPERSENSITIVITY IN IRRITABLE BOWEL SYNDROME
por: Pujo, J, et al.
Publicado: (2023)

A86 INFLAMMATORY BOWEL DISEASE PATIENTS’ SATISFACTION WITH TELEHEALTH: DURING THE COVID-19 PANDEMIC
por: Painchaud, M, et al.
Publicado: (2021)

A190 EPIDEMIOLOGY OF MUSCULOSKELETAL MANIFESTATIONS IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW
por: Ali, A, et al.
Publicado: (2022)

A98 FECAL LEUKOCYTE ESTERASE: AN ALTERNATIVE BIOMARKER TO FECAL CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE
por: Klemm, N K, et al.
Publicado: (2022)

A65 PREDICTING TRANSITION SUCCESS IN YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS
por: Bihari, A, et al.
Publicado: (2022)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

A183 SUCCINATE IN THE RELATIONSHIP BETWEEN INFLAMMATORY BOWEL DISEASE AND OBESITY IN SUCCINATE RECEPTOR DEFICIENT MICE
por: Arsenault, A M, et al.
Publicado: (2022)

A247 MEDITATION AND YOGA FOR IRRITABLE BOWEL SYNDROME (MY-IBS): A RANDOMIZED CONTROLLED TRIAL
por: D’Silva, A, et al.
Publicado: (2022)

A28 TIME-RESTRICTED FEEDING REDUCES INFLAMMATORY BOWEL DISEASE AND IMPROVES EPITHELIUM COLON REGENERATION
por: Carmona Alcocer, V, et al.
Publicado: (2023)

A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
por: Coward, S, et al.
Publicado: (2023)

A172 PSYCHOSOCIAL VARIABLES RELATED TO J-POUCH SURGERY FOR INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW
por: Hanna, Q, et al.
Publicado: (2022)

A173 EVALUATING VACCINATION IN INFLAMMATORY BOWEL DISEASE – A QUALITY ASSESSMENT STUDY IN THE WINNIPEG HEALTH REGION
por: Kundapur, P, et al.
Publicado: (2022)

A237 VIRULENCE POTENTIAL OF BACTERIA ISOLATED FROM NON-INFLAMED COLON IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Arjomand Fard, N, et al.
Publicado: (2022)

A159 OPIOID USE IS DECLINING AMONG PEOPLE WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED STUDY
por: Kuenzig, E, et al.
Publicado: (2022)

A76 MEDICATION ADHERENCE AND BELIEFS ABOUT MEDICATION AND THE CORRELATION WITH KNOWLEDGE ABOUT INFLAMMATORY BOWEL DISEASE (IBD) IN PREGNANCY
por: Govardhanam, V, et al.
Publicado: (2022)

A170 SERUM ALBUMIN AS A MEASURE OF INFLAMMATION OR MALNUTRITION IN INFLAMMATORY BOWEL DISEASE: A CROSS SECTIONAL STUDY
por: Squirell, E, et al.
Publicado: (2022)

A175 DISEASE ACTIVITY IN FIRST TRIMESTER IS ASSOCIATED WITH REDUCED GROWTH IN INFANTS BORN TO WOMEN WITH INFLAMMATORY BOWEL DISEASE
por: Wu, R Y, et al.
Publicado: (2022)

A171 EXPLORING PATIENT PERSPECTIVES ON A 12-WEEK, ONLINE STRESS REDUCTION INTERVENTION IN INFLAMMATORY BOWEL DISEASE
por: Hyde, A, et al.
Publicado: (2022)

A174 PERCEPTIONS OF CANNABIS USE IN WOMEN WITH INFLAMMATORY BOWEL DISEASE OF REPRODUCTIVE AGE: A CROSS-SECTIONAL STUDY
por: Tandon, P, et al.
Publicado: (2022)

A47 THE GUT MICROBIOTA INFLUENCES COLONIC HEALING AFTER SURGERY IN PATIENTS UNDERGOING BOWEL RESECTION FOR COLORECTAL CANCER
por: Hajjar, R, et al.
Publicado: (2023)

A52 SEX DIFFERENCES IN POST-INFLAMMATORY VISCERAL PAIN IN A MOUSE MODEL OF INFLAMMATORY BOWEL DISEASE (IBD)
por: Arzamendi, M, et al.
Publicado: (2023)

A34 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

A176 THE IMPACT OF COVID-19 ON ANXIETY, DEPRESSION, AND STRESS IN WOMEN WITH INFLAMMATORY BOWEL DISEASE: A CROSS-SECTIONAL SURVEY
por: Tandon, P, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_likns0rcb8h1nv17f1rdblg5bb